Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (20749)	5/14/1998 11:40:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

There are many ongoing clinical trials related to treating breast cancer. The halted PREVENTION trial for Tamoxifen had many sites (I not sure if Iowa was one) and I suspect that most or all of those sites will now participate in the new PREVENTION trial which uses Tamoxifen in one arm and Evista (Raloxifene) in the other. LGND's LLY deal includes exploring combinations of LLY's SERMs (like Evista or their 2nd generation compound) with LGND's rexinoids (like Targretin, LGD1268, or LGD1324). Such combinations have been shown to work in animals and next week data will be presented on treating human breast cancer with a combination of Tamoxifen and Panretin. Tamoxifen, like other SERMs (Drolixifene, CP-366,156, TSE424) acts as an anti-estrogen on breast cancers. Adramycin and taxotere are two chemotherapeutic agents that primarily target cell division (DNA and micotubules) while the compounds that I mentioned above are small molecules that influence intracellular hormone receptors.